Mobisyn Pain Relieving

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available text.

Uses and Indications

This drug is indicated for the temporary relief of minor pain associated with various conditions, including arthritis, simple backache, muscle strains, sprains, bruises, and cramps.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children over 12 years of age, the recommended method of administration involves using the roll-on applicator to apply a thin layer of the product to the affected area. The application should be followed by gentle massage into the painful area until the formulation is thoroughly absorbed into the skin. This process may be repeated as necessary, but should not exceed 3 to 4 applications within a 24-hour period. It is important to allow a minimum interval of 2 to 3 hours between each application to ensure safety and efficacy.

For children aged 12 years or younger, it is advised to consult a healthcare professional prior to use to determine the appropriate course of action.

Contraindications

Contact with eyes or mucous membranes should be avoided. The product must not be bandaged tightly or subjected to local heat, such as heating pads, at the application site. Additionally, it is contraindicated for use on wounds or on damaged, broken, or irritated skin.

Warnings and Precautions

For external use only. It is imperative that healthcare professionals advise patients to adhere strictly to this guideline to prevent unintended systemic exposure.

In the event of accidental ingestion, immediate medical assistance should be sought. Patients or caregivers are advised to contact a Poison Control Center without delay to ensure appropriate management of the situation.

Healthcare providers should instruct patients to discontinue use and consult their physician if any of the following occur: the condition worsens, symptoms persist for more than 7 days, or if symptoms resolve and then recur within a few days. Additionally, if excessive skin irritation develops, it is crucial to stop the treatment and seek medical advice promptly. Monitoring for these adverse effects is essential to ensure patient safety and effective management of their condition.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if the condition worsens, if symptoms persist for more than 7 days, or if symptoms clear up and then recur within a few days. Additionally, if excessive skin irritation occurs, medical advice should be sought.

Drug Interactions

There are no specific drug interactions reported for this medication. Additionally, no laboratory test interactions have been identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Mobisyn Pain Relieving (methyl salicylate and menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients 12 years of age or younger should consult a healthcare professional before use. It is important to assess the appropriateness of treatment and dosage for this age group, as specific recommendations may vary based on individual health needs and conditions.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients should consult a healthcare professional before using this medication. The safety of this drug during pregnancy has not been established, and potential risks to fetal outcomes are not fully understood. It is essential for women of childbearing potential to discuss their individual circumstances with their healthcare provider to weigh the benefits and risks associated with the use of this medication during pregnancy.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide the management of the overdose. Additionally, healthcare professionals should refer to local protocols and guidelines for the management of overdose situations, as these may provide specific recommendations based on the substance involved.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are available for the product associated with SPL code 90375-7.

Patient Counseling

Patients should be advised to seek immediate medical assistance or contact a Poison Control Center if the product is accidentally ingested. It is important for healthcare providers to instruct patients to monitor their condition closely; if symptoms worsen, persist for more than 7 days, or if symptoms resolve and then recur within a few days, patients should report these changes. Additionally, patients should be informed to discontinue use and consult a healthcare professional if excessive skin irritation occurs.

Patients must use the product only as directed and should be encouraged to read and follow all directions and warnings provided on the label. Healthcare providers should emphasize the importance of avoiding contact with the eyes or mucous membranes to prevent irritation.

Patients should also be cautioned against bandaging the area tightly or applying local heat, such as heating pads, to the site of application. It is critical to avoid applying the product to wounds or damaged, broken, or irritated skin. Finally, patients should be reminded to wash their hands thoroughly after using the product to prevent unintentional exposure.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure to protect its quality. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

Patients should be advised that the product is for external use only and must be applied as directed. For adults and children over 12 years, the recommended method of administration involves using the roll-on applicator to apply a thin layer to the affected area, massaging it into the skin until fully absorbed. Applications may be repeated as necessary, but should not exceed 3 to 4 times daily, with a minimum interval of 2-3 hours between applications.

Clinicians should counsel patients to avoid contact with eyes and mucous membranes, and to refrain from tightly bandaging or applying local heat to the treated area. The product should not be applied to wounds or damaged skin, and hands should be washed after use. Patients are advised to discontinue use and consult a doctor if the condition worsens, symptoms persist beyond 7 days, or if excessive skin irritation occurs. Pregnant or breastfeeding individuals should seek professional advice before use. Additionally, the product should be kept out of reach of children, and in case of accidental ingestion, medical assistance or contact with a Poison Control Center is recommended.

Drug Information (PDF)

This file contains official product information for Mobisyn Pain Relieving, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)